BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 26063725)

  • 1. Aberrant TET1 Methylation Closely Associated with CpG Island Methylator Phenotype in Colorectal Cancer.
    Ichimura N; Shinjo K; An B; Shimizu Y; Yamao K; Ohka F; Katsushima K; Hatanaka A; Tojo M; Yamamoto E; Suzuki H; Ueda M; Kondo Y
    Cancer Prev Res (Phila); 2015 Aug; 8(8):702-11. PubMed ID: 26063725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels.
    Lee S; Cho NY; Yoo EJ; Kim JH; Kang GH
    Arch Pathol Lab Med; 2008 Oct; 132(10):1657-65. PubMed ID: 18834226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway.
    Kim JH; Bae JM; Cho NY; Kang GH
    Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TET1 and TDG Suppress Inflammatory Response in Intestinal Tumorigenesis: Implications for Colorectal Tumors With the CpG Island Methylator Phenotype.
    Tricarico R; Madzo J; Scher G; Cohen M; Jelinek J; Maegawa S; Nagarathinam R; Scher C; Chang WC; Nicolas E; Slifker M; Zhou Y; Devarajan K; Cai KQ; Kwok T; Nakajima P; Xu J; Mancuso P; Doneddu V; Bagella L; Williams R; Balachandran S; Maskalenko N; Campbell K; Ma X; Cañadas I; Viana-Errasti J; Moreno V; Valle L; Grivennikov S; Peshkova I; Kurilenko N; Mazitova A; Koltsova E; Lee H; Walsh M; Duttweiler R; Whetstine JR; Yen TJ; Issa JP; Bellacosa A
    Gastroenterology; 2023 May; 164(6):921-936.e1. PubMed ID: 36764492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular dissection of premalignant colorectal lesions reveals early onset of the CpG island methylator phenotype.
    Yamamoto E; Suzuki H; Yamano HO; Maruyama R; Nojima M; Kamimae S; Sawada T; Ashida M; Yoshikawa K; Kimura T; Takagi R; Harada T; Suzuki R; Sato A; Kai M; Sasaki Y; Tokino T; Sugai T; Imai K; Shinomura Y; Toyota M
    Am J Pathol; 2012 Nov; 181(5):1847-61. PubMed ID: 22995252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features.
    Zlobec I; Bihl M; Foerster A; Rufle A; Lugli A
    J Pathol; 2011 Nov; 225(3):336-43. PubMed ID: 21660972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are clinicopathological features of colorectal cancers with methylation in half of CpG island methylator phenotype panel markers different from those of CpG island methylator phenotype-high colorectal cancers?
    Bae JM; Rhee YY; Kim KJ; Wen X; Song YS; Cho NY; Kim JH; Kang GH
    Hum Pathol; 2016 Jan; 47(1):85-94. PubMed ID: 26520418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-wide methylation analysis identifies a core set of hypermethylated genes in CIMP-H colorectal cancer.
    McInnes T; Zou D; Rao DS; Munro FM; Phillips VL; McCall JL; Black MA; Reeve AE; Guilford PJ
    BMC Cancer; 2017 Mar; 17(1):228. PubMed ID: 28351398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
    Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
    Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
    Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
    Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.
    Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
    Hum Pathol; 2007 Apr; 38(4):614-20. PubMed ID: 17270239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations.
    Ogino S; Kawasaki T; Kirkner GJ; Loda M; Fuchs CS
    J Mol Diagn; 2006 Nov; 8(5):582-8. PubMed ID: 17065427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CpG island methylator phenotype correlates with long-range epigenetic silencing in colorectal cancer.
    Karpinski P; Ramsey D; Grzebieniak Z; Sasiadek MM; Blin N
    Mol Cancer Res; 2008 Apr; 6(4):585-91. PubMed ID: 18403637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high.
    Ogino S; Kawasaki T; Kirkner GJ; Ohnishi M; Fuchs CS
    BMC Cancer; 2007 May; 7():72. PubMed ID: 17474983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WRN promoter methylation possibly connects mucinous differentiation, microsatellite instability and CpG island methylator phenotype in colorectal cancer.
    Kawasaki T; Ohnishi M; Suemoto Y; Kirkner GJ; Liu Z; Yamamoto H; Loda M; Fuchs CS; Ogino S
    Mod Pathol; 2008 Feb; 21(2):150-8. PubMed ID: 18084250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies.
    Ogino S; Cantor M; Kawasaki T; Brahmandam M; Kirkner GJ; Weisenberger DJ; Campan M; Laird PW; Loda M; Fuchs CS
    Gut; 2006 Jul; 55(7):1000-6. PubMed ID: 16407376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer.
    Ogino S; Kawasaki T; Kirkner GJ; Ogawa A; Dorfman I; Loda M; Fuchs CS
    J Pathol; 2006 Oct; 210(2):147-54. PubMed ID: 16850502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TET1 Depletion Induces Aberrant CpG Methylation in Colorectal Cancer Cells.
    Kai M; Niinuma T; Kitajima H; Yamamoto E; Harada T; Aoki H; Maruyama R; Toyota M; Sasaki Y; Sugai T; Tokino T; Nakase H; Suzuki H
    PLoS One; 2016; 11(12):e0168281. PubMed ID: 27977763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic Risk Factor Distributions for MLH1 Promoter Region Methylation in CIMP-Positive Tumors.
    Levine AJ; Phipps AI; Baron JA; Buchanan DD; Ahnen DJ; Cohen SA; Lindor NM; Newcomb PA; Rosty C; Haile RW; Laird PW; Weisenberger DJ
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):68-75. PubMed ID: 26512054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decrease of 5hmC in gastric cancers is associated with TET1 silencing due to with DNA methylation and bivalent histone marks at TET1 CpG island 3'-shore.
    Park JL; Kim HJ; Seo EH; Kwon OH; Lim B; Kim M; Kim SY; Song KS; Kang GH; Kim HJ; Choi BY; Kim YS
    Oncotarget; 2015 Nov; 6(35):37647-62. PubMed ID: 26462176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.